Skip to main content
. 2019 Jun 17;11(6):838. doi: 10.3390/cancers11060838

Figure 2.

Figure 2

Different EMT-driven mechanisms leading to carboplatin and/or paclitaxel resistance in ovarian cancer cells: the presence of β-tubulin variants; lower drug uptake; higher drug efflux; increased DNA repair capacity; decreased apoptosis; changes in the cell cycle; changes in miRNA; and changes in different pathways (MAPK/ERK, TGFβ-SMAD, JAK/STAT, PI3K-AKT-NFκB). In addition, factors secreted by the microenvironment can induce EMT-related therapy resistance.